Next 10 |
home / stock / phcuf / phcuf news
The following slide deck was published by Photocure ASA in conjunction with their 2023 Q4 earnings call. For further details see: Photocure ASA 2023 Q4 - Results - Earnings Call Presentation
Photocure ASA press release ( OTC:PHCUF ): Q4 GAAP EPS of -NOK 0.79. Revenue of NOK 104.2M (+10.3% Y/Y). The EBIT was -NOK 23.1 million (-NOK 11.5 million) and the cash balance at the end of the third quarter 2022 was NOK 268.1 million. "We expect to deliver Hex...
Summary Insilico Medicine signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Wuhan Neurophth announced a $140 million agreement to use Cyagen’s AI platform to discover novel AAV vectors. Harbour BioMed will use its antibody disc...
Photocure ASA press release ( OTC:PHCUF ): Q3 GAAP EPS of -NOK 0.37. Revenue of NOK 106.8M (+22.2% Y/Y). EBIT was NOK -1.4M and the cash balance at the end of Q3 2022 was NOK 283.9M. For further details see: Photocure ASA GAAP EPS of -NOK 0.37, rev...
The following slide deck was published by Photocure ASA in conjunction with their 2022 Q2 earnings call. For further details see: Photocure ASA 2022 Q2 - Results - Earnings Call Presentation
Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial PR Newswire OSLO, Norway , Aug. 9, 2022 /PRNewswire/ -- On August 9, 2022 , Asieris Pharmaceuticals, a global biopharmaceutical company specializ...
Photocure ASA: Results for the first quarter of 2022 PR Newswire OSLO, Norway , May 11, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 81.4 million in the first quarter of 2022 (Q1 ...
Photocure (OTC:PHCUF) said its partner Asieris Pharma received an approval to conduct a real-world evidence study of its drug Hexvix for bladder cancer in China's Hainan province, in addition to a phase 3 study approved last month. Hexvix (hexaminolevulinate HCl), which is...
Photocure Partner Asieris announces CDE Approval for Hexvix Clinical Real-World Evidence Study in China PR Newswire OSLO, Norway , March 11, 2022 /PRNewswire/ -- Photocure ASA ( PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharm...
Photocure ASA press release (OTC:PHCUF): Q4 GAAP EPS of -NOK 1.05. Revenue of NOK 94.5M (-3.5% Y/Y). EBITDA before restructuring for the fourth quarter was -NOK 5.5M. Cash balance at the end of the fourth quarter of 2021 was NOK 322.9 million (NOK 334.9 million). Net cash used in the fou...
News, Short Squeeze, Breakout and More Instantly...
Photocure Asa Company Name:
PHCUF Stock Symbol:
OTCMKTS Market:
Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial PR Newswire OSLO, Norway , Aug. 9, 2022 /PRNewswire/ -- On August 9, 2022 , Asieris Pharmaceuticals, a global biopharmaceutical company specializ...
Photocure ASA: Results for the first quarter of 2022 PR Newswire OSLO, Norway , May 11, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 81.4 million in the first quarter of 2022 (Q1 ...
Photocure Partner Asieris announces CDE Approval for Hexvix Clinical Real-World Evidence Study in China PR Newswire OSLO, Norway , March 11, 2022 /PRNewswire/ -- Photocure ASA ( PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharm...